NCT02792179View on ClinicalTrials.gov

Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 19, 2016

Primary Completion Date

September 28, 2016

Study Completion Date

September 28, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

[18F]RO6958948

Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of \[18F\]RO6958948 injected will be less than or equal to (\</=) 10 micrograms (µg), injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie \[mCi\]).

Trial Locations (1)

21287-0807

Johns Hopkins Medical Institutions, Johns Hopkins Outpatient Center, Baltimore

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02792179 - Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants | Biotech Hunter | Biotech Hunter